157 related articles for article (PubMed ID: 19053774)
1. New benzylureas as a novel series of potent, nonpeptidic vasopressin V2 receptor agonists.
Yea CM; Allan CE; Ashworth DM; Barnett J; Baxter AJ; Broadbridge JD; Franklin RJ; Hampton SL; Hudson P; Horton JA; Jenkins PD; Penson AM; Pitt GR; Rivière P; Robson PA; Rooker DP; Semple G; Sheppard A; Haigh RM; Roe MB
J Med Chem; 2008 Dec; 51(24):8124-34. PubMed ID: 19053774
[TBL] [Abstract][Full Text] [Related]
2. Pyridobenzodiazepines: a novel class of orally active, vasopressin V2 receptor selective agonists.
Failli AA; Shumsky JS; Steffan RJ; Caggiano TJ; Williams DK; Trybulski EJ; Ning X; Lock Y; Tanikella T; Hartmann D; Chan PS; Park CH
Bioorg Med Chem Lett; 2006 Feb; 16(4):954-9. PubMed ID: 16297621
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
Pena A; Murat B; Trueba M; Ventura MA; Wo NC; Szeto HH; Cheng LL; Stoev S; Guillon G; Manning M
J Med Chem; 2007 Feb; 50(4):835-47. PubMed ID: 17300166
[TBL] [Abstract][Full Text] [Related]
4. Identification of novel selective V2 receptor non-peptide agonists.
Del Tredici AL; Vanover KE; Knapp AE; Bertozzi SM; Nash NR; Burstein ES; Lameh J; Currier EA; Davis RE; Brann MR; Mohell N; Olsson R; Piu F
Biochem Pharmacol; 2008 Oct; 76(9):1134-41. PubMed ID: 18761325
[TBL] [Abstract][Full Text] [Related]
5. Characterization of RWJ-351647, a novel nonpeptide vasopressin V2 receptor antagonist.
Gunnet JW; Matthews JM; Maryanoff BE; de Garavilla L; Andrade-Gordon P; Damiano B; Hageman W; Look R; Stahle P; Streeter AJ; Wines PG; Demarest KT
Clin Exp Pharmacol Physiol; 2006 Apr; 33(4):320-6. PubMed ID: 16620295
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a novel, potent and orally active series of gamma-lactams as selective NK1 antagonists.
Paliwal S; Reichard GA; Shah S; Wrobleski ML; Wang C; Stengone C; Tsui HC; Xiao D; Duffy RA; Lachowicz JE; Nomeir AA; Varty GB; Shih NY
Bioorg Med Chem Lett; 2008 Jul; 18(14):4168-71. PubMed ID: 18547807
[TBL] [Abstract][Full Text] [Related]
7. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.
Manning M; Stoev S; Chini B; Durroux T; Mouillac B; Guillon G
Prog Brain Res; 2008; 170():473-512. PubMed ID: 18655903
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and evaluation of orally active inhibitors of plasminogen activator inhibitor-1 (PAI-1) production.
Miyazaki H; Ogiku T; Sai H; Ohmizu H; Murakami J; Ohtani A
Bioorg Med Chem Lett; 2008 Dec; 18(24):6419-22. PubMed ID: 18993062
[TBL] [Abstract][Full Text] [Related]
9. Preparation of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetamide derivatives as novel arginine vasopressin V(2) receptor agonists.
Tsukamoto I; Koshio H; Akamatsu S; Kuramochi T; Saitoh C; Yatsu T; Yanai-Inamura H; Kitada C; Yamamoto E; Sakamoto S; Tsukamoto S
Bioorg Med Chem; 2008 Nov; 16(21):9524-35. PubMed ID: 18835174
[TBL] [Abstract][Full Text] [Related]
10. Novel design of nonpeptide AVP V(2) receptor agonists: structural requirements for an agonist having 1-(4-aminobenzoyl)-2,3,4, 5-tetrahydro-1H-1-benzazepine as a template.
Kondo K; Ogawa H; Shinohara T; Kurimura M; Tanada Y; Kan K; Yamashita H; Nakamura S; Hirano T; Yamamura Y; Mori T; Tominaga M; Itai A
J Med Chem; 2000 Nov; 43(23):4388-97. PubMed ID: 11087564
[TBL] [Abstract][Full Text] [Related]
11. The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.
Westaway SM; Brown SL; Conway E; Heightman TD; Johnson CN; Lapsley K; Macdonald GJ; MacPherson DT; Mitchell DJ; Myatt JW; Seal JT; Stanway SJ; Stemp G; Thompson M; Celestini P; Colombo A; Consonni A; Gagliardi S; Riccaboni M; Ronzoni S; Briggs MA; Matthews KL; Stevens AJ; Bolton VJ; Boyfield I; Jarvie EM; Stratton SC; Sanger GJ
Bioorg Med Chem Lett; 2008 Dec; 18(24):6429-36. PubMed ID: 19006669
[TBL] [Abstract][Full Text] [Related]
12. Potent nonpeptide vasopressin receptor antagonists based on oxazino- and thiazinobenzodiazepine templates.
Matthews JM; Hoekstra WJ; Dyatkin AB; Hecker LR; Hlasta DJ; Poulter BL; Andrade-Gordon P; de Garavilla L; Demarest KT; Ericson E; Gunnet JW; Hageman W; Look R; Moore JB; Reynolds CH; Maryanoff BE
Bioorg Med Chem Lett; 2004 Jun; 14(11):2747-52. PubMed ID: 15125926
[TBL] [Abstract][Full Text] [Related]
13. Discovery of Potent, Selective, and Short-Acting Peptidic V
Wiśniewski K; Qi S; Kraus J; Ly B; Srinivasan K; Tariga H; Croston G; La E; Wiśniewska H; Ortiz C; Laporte R; Rivière PJ; Neyer G; Hargrove DM; Schteingart CD
J Med Chem; 2019 May; 62(10):4991-5005. PubMed ID: 31022340
[TBL] [Abstract][Full Text] [Related]
14. Optimization of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine-5-ylidene)acetamide derivatives as arginine vasopressin V2 receptor agonists and discussion of their binding modes.
Tsukamoto I; Koshio H; Orita M; Saitoh C; Yanai-Inamura H; Kitada-Nozawa C; Yamamoto E; Yatsu T; Sakamoto S; Tsukamoto S
Bioorg Med Chem; 2009 Dec; 17(24):8161-7. PubMed ID: 19900813
[TBL] [Abstract][Full Text] [Related]
15. Aryl sulphonyl amides as potent agonists of the growth hormone secretagogue (ghrelin) receptor.
Witherington J; Abberley L; Bellenie BR; Boatman R; Collis K; Dean DK; Gaiba A; King NP; Shuker N; Steadman JG; Takle AK; Sanger G; Butler S; McKay F; Muir A; Winborn K; Ward RW; Heightman TD
Bioorg Med Chem Lett; 2009 Feb; 19(3):684-7. PubMed ID: 19128969
[TBL] [Abstract][Full Text] [Related]
16. Discovery of 3-aryl-5-aryl-1,2,4-oxadiazoles as a new series of apoptosis inducers. 2. Identification of more aqueous soluble analogs as potential anticancer agents.
Kemnitzer W; Kuemmerle J; Zhang HZ; Kasibhatla S; Tseng B; Drewe J; Cai SX
Bioorg Med Chem Lett; 2009 Aug; 19(15):4410-5. PubMed ID: 19500976
[TBL] [Abstract][Full Text] [Related]
17. Identification of small molecule agonists of the motilin receptor.
Heightman TD; Conway E; Corbett DF; Macdonald GJ; Stemp G; Westaway SM; Celestini P; Gagliardi S; Riccaboni M; Ronzoni S; Vaidya K; Butler S; McKay F; Muir A; Powney B; Winborn K; Wise A; Jarvie EM; Sanger GJ
Bioorg Med Chem Lett; 2008 Dec; 18(24):6423-8. PubMed ID: 18980843
[TBL] [Abstract][Full Text] [Related]
18. The effect of vasopressin and related compounds at V1a and V2 receptors in animal models relevant to human disease.
Petersen MB
Basic Clin Pharmacol Toxicol; 2006 Aug; 99(2):96-103. PubMed ID: 16918709
[TBL] [Abstract][Full Text] [Related]
19. Identification and initial evaluation of 4-N-aryl-[1,4]diazepane ureas as potent CXCR3 antagonists.
Cole AG; Stroke IL; Brescia MR; Simhadri S; Zhang JJ; Hussain Z; Snider M; Haskell C; Ribeiro S; Appell KC; Henderson I; Webb ML
Bioorg Med Chem Lett; 2006 Jan; 16(1):200-3. PubMed ID: 16213722
[TBL] [Abstract][Full Text] [Related]
20. Comparative pharmacology of bovine, human and rat vasopressin receptor isoforms.
Andrés M; Peña A; Derick S; Raufaste D; Trojnar J; Wisniewski K; Trueba M; Serradeil-Le Gal C; Guillon G
Eur J Pharmacol; 2004 Oct; 501(1-3):59-69. PubMed ID: 15464063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
